Loading...

Industry Workshops

CSCC 2022 | June 5-8 | Niagara Falls Ontario > Industry Workshops

Industry Workshops will be held on Monday, June 6 and Tuesday, June 7:

 

Monday June 6 Afternoon Part 1 – 1400-1500

Monday June 6 Afternoon Part 2 – 1600-1700

Tuesday June 7 Breakfast – 0730-0830

Back to top

 

The Binding SiteI061400-A Insight in the future of monoclonal protein quantification: The Mass Spectrometry Solution
hosted by The Binding Site
Monday June 6, 1400-1500

 

Frank Courjal, PhD, Director of Scientific Affairs in Canada, The Binding Site

 

Learning Objectives:

At the end of the session, the participants will be able to:

  • Understand limitations of serum/urine protein electrophoresis and immunofixation.
  • Discuss the basic concepts of monoclonal protein quantification by mass spectrometry.
  • Describe the advantages of mass spectrometry solution.
  • Compare mass spectrometry with other technologies in the evaluation of minimal residual disease.

Monoclonal proteins are a key biomarker for diagnosis, monitoring and prognosis of monoclonal gammopathies. For the last century, serum and urine protein electrophoresis and immunofixation have been the reference methods to follow this biomarker. The addition of serum free light chain and serum heavy/light chain quantification by turbidimetry in the last decades brought a higher level of specificity and sensitivity as well as automation for an improvement of monoclonal protein detection. However, with the new treatments (i.e., monoclonal antibody therapies) and the deepness of patient responses to treatments, more sensitive and more specific methodologies are requested in an environment where automation, fast turnaround time, less hands-on time, objective interpretations and standardization are essential. The mass spectrometry solution is the answer to these needs.

Back to top

 

 

Siemens HealthineersI061400-B Got Data? Integrating data into meaningful workflow and AI-based decision support tools for today’s clinical laboratory
hosted by Siemens Healthineers
Monday June 6, 1400-1500

 

Emmananuel Quiazon, Siemens Healthineers

Jennifer Sanderson, Siemens Healthineers

 

Learning Objectives:

At the end of the session, the participants will be able to:

  • Understand what method validation tools are integrated into modern diagnostic equipment software.
  • Understand the powerful data workflow and decision support tools included in the latest generation of laboratory middleware.
  • Describe the future of advanced patient workflow management using integrated Artificial Intelligence.
  • Understand the power of real-time, fully integrated, and customizable KPI data, consolidated from instrument, automation, and LIS data sources.

The clinical laboratory is increasingly reliant on modern data management tools to manage critical tasks including method validation, advanced patient workflow and the measurement of Key Performance Indicators (KPI) in real-time. In this presentation we will discuss various tools and features currently integrated into analyzer software and middleware solutions as well as tools in development. These tools are designed to provide easy, flexible access to information by the clinical biochemist. We will also discuss the ability of the laboratory management team to access a suite of highly customizable KPI tools which integrate data from multiple sources.

Back to top

 

 

AbbottI061400-C Saving lives using high sensitivity troponin-I with best practice examples of mitigated cardiovascular risk and death associated with post-operative care following cardiac surgery as well as routine Annual Health Assessments
hosted by Abbott Laboratories Inc.
Monday June 6, 1400-1500

 

Andre Lamy, Cardiac Surgeon, Hamilton Health Sciences; Professor, Department of Surgery, McMaster University

Peter Nord, Chief Medical Officer, Medcan

Tricia Ravalico, Director of Global Scientific Leadership and Education, Abbott Laboratories Inc.

 

Learning Objectives:

At the end of the session, the participants will be able to:

  • Recognize the prognostic power of hsTn-I for enhanced cardiovascular risk mitigation in settings outside of acute myocardial infarction.
  • Understand landmark findings from the recently published CARDIAC VISION study including expected changes in upcoming recommendations related to relevant thresholds for the application of hsTnI for the detection of perioperative myocardial infarction and clinically important perioperative myocardial injury.
  • Highlight the substantial benefits of cardiac health screening for patients, payors, clinicians and the health ecosystem via strategic implementation of high-sensitivity troponin-I for measurably better healthcare.

High-sensitivity cardiac troponin assays have long been endorsed as the preferred biomarker for the clinical diagnosis of acute myocardial infarction. Substantial evidence has since emerged to utilize this biomarker for prognostic value in other clinical settings, including but not limited to healthy patient screening and peri-operative surgical care. This workshop will cover both extremes, beginning with the unveiling of the recent and landmark findings from the Vascular Events in Surgery Patients Cohort Evaluation (VISION) Cardiac Surgery study which examined clinical outcomes of patients following cardiac surgery. With a primary objective of determining the relationship between postoperative high-sensitivity cardiac troponin I levels and the risk of death within 30 days after cardiac surgery, their game-changing outcomes are expected to change clinical practice. Similarly, the novel implementation of high sensitivity cardiac troponin-I in annual cardiovascular health assessments has led to numerous case examples of life-changing interventions, enhanced risk identification of subclinical injury, as well as immeasurable cost savings across the health ecosystem.

Back to top

 

 

RocheI061400-D Cybersecurity and digital solutions; new challenges of healthcare
hosted by Roche Diagnostics
Monday June 6, 1400-1500

 

Tom Pendergast, CISSP, Director, Product Cyber Security, Roche Diagnostics United States

 

Learning Objectives:

  • Understand the true meaning of “shared responsibility.
  • The vendor’s responsibility for the vendor’s system.
  • Goal: Making IT / Cyber teams work less.

This session is designed to help attendees better understand the challenges associated with cybersecurity in the healthcare environment. During this open discussion, cybersecurity experts will share what keeps them up at night, what lessons they have learned and their vision for better data protection. No organization can be alone in this new digital environment – we are hoping to share knowledge and insights with members of C-Suite, Clinical Biochemists and Lab Managers. Attendees will learn key concepts and acquire knowledge to continue discussions about the security of their lab environment.

In 2017, critical data from major healthcare organizations were compromised during the WannaCry ransomware attack. It was one of the first major demonstrations of the healthcare sector’s vulnerability. Several health institutions were affected and millions of patient’s personal information were compromised. The world healthcare systems had to learn from this experience and adjust to this new reality. Healthcare data is very valuable; a new currency in the black market even; more than 50 times compared to payment cards. Now more than ever, the protection of data is everyone’s responsibility.

Back to top

 

 

Beckman CoulterI061600-A Severe Infection and Monocyte Distribution Width (MDW)
hosted by Beckman Coulter
Monday June 6, 1600-1700

 

Steve Ness, Director, Medical and Scientific Affairs, Beckman Coulter

 

Learning Objectives:

Participants will gain a better understanding of:

  • The relationship between severe infection, sepsis and MDW.
  • How MDW is measured.
  • Challenges in diagnosing severe infection and sepsis early.
  • The relationship between COVID-19 and MDW.
  • Review of current publications and literature.

The workshop will focus on reducing diagnostic uncertainty early for the successful treatment of severe infection, sepsis and COVID-19. A new and novel biomarker, monocyte distribution width (MDW) is liked very early these patients and early diagnoses can affect better outcomes.

Back to top

 

 

SebiaI061600-B Immunotyping Electrophoresis: Performance and Practicalities
hosted by Sebia Canada
Monday June 6, 1600-1700

 

Bonnie Cheung, Sebia Canada

David Grenache, PhD, MT(ASCP), D(ABCC), FAACC, Chief Scientific Officer, TriCore Reference Laboratories

Katie Thoren, PhD, D(ABCC), FAACC, Associate Professor, Director of Advanced Protein Diagnostics Laboratory, University of Miami

 

Learning Objectives:

At the end of the session, the participants will be able to:

  • Discuss the advantages and limitations of IT and IF in detecting monoclonal proteins.
  • Describe how an IT training program can improve IT interpretation skills.
  • Describe how IT can be used in combination with other assays to screen and monitor monoclonal gammopathies.
  • List practical advantages of IT over IF.

Immunotyping (IT) by capillary electrophoresis offers a more automated solution than immunofixation (IF) to confirm the presence of a monoclonal protein and determine its isotype. In this session, Dr. Katie Thoren will present data from a recent study comparing the performance of IT to IF. She will discuss the importance of reviewer training, the analytical and clinical sensitivity of IT and IF, the limitations of each test and potential strategies for mitigating these limitations. Dr. David Grenache will discuss the use of IT for screening and monitoring monoclonal gammopathies. He will review the practical advantages/disadvantages of IT, the testing workflows and reflex strategies used in his laboratory, and guidelines for screening.

Back to top

 

 

HLS TherapeuticsI061600-C Modernizing schizophrenia patient management with rapid blood tests for antipsychotic medication levels
hosted by HLS Therapeutics
Monday June 6, 1600-1700

 

William Clarke, MBA, PhD, DABCC, FAACC, Director, Clinical Toxicology, Director, Point-of-Care Testing, Co-Director, Clinical Chemistry Post-Doctoral Fellowship Program, Medicine; Professor of Pathology, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine

 

Learning Objectives:

At the end of the session, the participants will be able to:

  • Identify the clinical gaps in the schizophrenia patient`s care journey.
  • Define the appropriate clinical application of clozapine TDM.
  • Interpret clinical guidance for optimal utilization of assays for antipsychotic TDM.

Rapid blood tests for antipsychotics medication levels.

Back to top

 

 

Nova BiomedicalI061600-D Improving Blood Testing for Patients with Diabetes
hosted by Nova Biomedical
Monday June 6, 1600-1700

 

Naveen Bangia, PhD, Director, Medical and Scientific Affairs, Nova Biomedical

 

Learning Objectives:

At the end of the session, the participants will be able to:

  • Understand some of the interfering substances in glucose measurement.
  • Learn the consequences of potential interferences.
  • Identify technologies that have minimal interference when testing for glucose levels in blood.
  • Recognize and detect magnesium imbalance in patients with diabetes.

Diabetes is well known to be a disease of dysregulated glucose where monitoring of blood glucose level is critical to guide therapy and avoid complications such as kidney damage. However, less well appreciated is the magnesium imbalance that occurs in these patients. In this presentation, Dr. Naveen Bangia reviews literature surrounding testing for patients with diabetes, including testing for magnesium imbalance and overcoming limitations in blood glucose testing methodologies.

Back to top

 

 

Quidel CanadaI070730-A Addressing the continuum of cardiac troponin testing needs in hospital and decentralized environments
hosted by Quidel Canada
Tuesday June 7, 0730-0830

 

Robert H. Christenson, Professor of Pathology, Professor of Medical and Research Technology, Medical Director of Core Laboratories, Medical Director of Point of Care Services, Editor-in-Chief, University of Maryland School of Medicine, the Journal of Applied Laboratory Medicine

 

Learning Objectives:

At the end of the session, the participants will be able to:

  • Explain the principle clinical benefits of having a high-sensitivity (hs)-TnI assay and the flexibility of a decentralized measurement with laboratory performance.
  • Compare and contrast the validation processes for POC versus Central Lab for hs-TnI assays.
  • Explain how to meet the challenges associated with use of algorithms in both hospital and decentralized options.

How to meet the need for highly sensitive and precise cardiac troponin results in diverse care venues is a primary aim of this session. The focus is flexible technologies that deliver central lab quality results without complicated equipment, regardless of whether measurements are conducted by a laboratorian or other healthcare professional.

Back to top

 

 

Ortho Clinical DiagnosticsI070730-B Use of Procalcitonin for Antimicrobial Stewardship in Sepsis
hosted by Ortho Clinical Diagnostics
Tuesday June 7, 0730-0830

 

Michael S. Niederman, M.D., MACP, FFCCP, FCCM, FERS, Professor of Clinical Medicine, Weill Cornell Medical College

Learning Objectives:

At the end of the session, the participants will be able to:

  • Discuss the role of biomarkers in guiding antibiotic use in the ICU.
  • Discuss the role of biomarkers for patients with COVID 19.
  • Explore ways to incorporate biomarker measurement into antimicrobial stewardship.

Use of Biomarkers for Antimicrobial Stewardship in Community-Acquired Pneumonia and Sepsis in the ICU.

Back to top